Breaking Canadian GLP-1 news
GLP-1 News — Page 9
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Where are you in your GLP-1 journey?
Answer a few quick questions — get your cheapest path to a GLP-1 prescription, free.
Canada's Drug Agency to Decide Mounjaro Coverage Within Weeks
Canada's Drug Agency expected to announce public plan coverage decision for Eli Lilly's Mounjaro within weeks, affecting provincial formulary access.
Alberta Blue Cross Reports Second Wave GLP-1 Innovation for 2026
Alberta Blue Cross drug pipeline report highlights improved formulations and expanded applications driving continued GLP-1 therapy growth in 2026.
Novo Nordisk Launches $199 Introductory Price for Low-Dose GLP-1s
Novo Nordisk introduces $199 monthly pricing for starter doses of Wegovy and Ozempic in Canada, expanding access ahead of generic competition.
Hims & Hers Launches Canadian Operations Ahead of Generic GLP-1s
US telemedicine company Hims & Hers expands into Canada as the country prepares for generic semaglutide availability starting mid-2026.
GLP-1 Drugs Drive Major Canadian Employer Drug Plan Cost Increases
New Benefits Canada report reveals GLP-1 medications are a major driver of employer drug plan cost increases in 2026 despite expected generic approvals.
Canada's Drug Agency Estimates Wegovy Costs $5,000 Annually
Canada's Drug Agency releases official annual cost estimate of $5,000 for Wegovy based on recommended maintenance dose, providing new government costing data.
Generic Semaglutide Could Cut Canadian Drug Costs by 65%
Benefits industry analysis projects 65% price reduction for generic semaglutide in Canada as Health Canada reviews nine applications from manufacturers.
Health Canada Adds Submission Class Data to Drug Review Tracker
Health Canada enhanced its public drug review tracker on March 20, 2026, adding submission class information to help Canadians track generic applications.
GLP-1 Drug Costs Could Drop from $400 to $15 Monthly in Canada
Current $300-400 monthly costs for Ozempic and Wegovy could fall to $15 with generic competition, representing a 96% price reduction for Canadian patients.
Generic Semaglutide Manufacturing Begins at Canadian Facilities
Canadian pharmaceutical companies have begun production of generic semaglutide at domestic manufacturing facilities ahead of regulatory approvals.
Health Canada Approves Rybelsus for Heart Disease Prevention
Health Canada expands Rybelsus approval to reduce major cardiovascular events in adults with Type 2 diabetes and heart disease risk factors.
Health Canada May Approve First Generic Semaglutide May-September
Industry sources indicate Health Canada could approve the first generic semaglutide between May and September 2026, marking a narrower timeline than previous estimates.
Dr. Reddy's, Sun Pharma Apply for Generic Semaglutide in Canada
Two major Indian pharmaceutical companies have submitted applications to Health Canada for generic semaglutide approval, joining the competitive race.
Aspen Pharma Targets Q3 2026 Generic Semaglutide Launch
Aspen Pharmacare sets specific third quarter 2026 target for generic semaglutide launch in Canada, joining nine companies seeking Health Canada approval.
Vimy Pharma to File Generic Semaglutide Application Soon
Edmonton-based Vimy Pharma expects to submit its Health Canada application for generic semaglutide within weeks, joining eight other companies in review.
Health Canada Adds Submission Class Data to Public Tracker
Health Canada's drug review tracker now shows submission 'class' details including Access Consortium reviews as of March 20, expanding transparency.
Eli Lilly Cuts U.S. Zepbound Price Following Canada Reductions
Eli Lilly reduces U.S. Zepbound pricing for single-dose vials after cutting Canadian prices 20% in December, expanding affordability strategy globally.
Pfizer Develops Long-Acting GLP-1 Drug to Challenge Market
Pfizer is developing a long-acting GLP-1 drug that could compete directly with Eli Lilly's Mounjaro and Zepbound when it reaches the Canadian market.
Health Canada Adds New Tracking Features for Generic Reviews
Health Canada's March 20 update to drug review tracking now shows submission class and Access Consortium status for all completed reviews including generics.
3 Million Canadians Use GLP-1 Drugs, Survey Reveals High Demand
New survey data shows approximately 3 million Canadian adults currently take GLP-1 medications like Ozempic and Mounjaro, with many more seeking access.
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada